The Global Polio Eradication Initiative (GPEI) was established in 1988 by the World Health Assembly to interrupt transmission of wild poliovirus (WPV); completion of this initiative was declared a programmatic emergency of public health in January 2012 (1, 2) . Polio cases are detected through surveillance for acute flaccid paralysis (AFP) with linked stool specimens tested for polioviruses (PVs) at accredited laboratories within the Global Polio Laboratory Network (GPLN). AFP surveillance findings are supplemented by testing sewage samples (environmental surveillance) collected at selected sites. Virologic data guide where targeted immunization activities should be conducted or improved. Key performance indicators are used to 1) monitor AFP surveillance quality at national and subnational levels to identify gaps where PV transmission could occur undetected; 2) provide evidence of where PV circulation has been interrupted; and 3) allow timely detection of an outbreak. Standardized surveillance indicators allow progress to be monitored over time and compared among countries (3) . This report presents AFP surveillance performance indicators at national and subnational levels for countries affected by polio during 2011-2012, and trends in environmental surveillance, updating previous reports (4, 5) . In the 19 countries with transmission of PV (WPV and/ or circulating vaccine-derived poliovirus [cVDPV]) during 2011-2012, national performance indicator targets were met in 12 (63%) countries in 2011 and 13 (68%) countries in 2012. Seven countries (37%) in 2011 had ≥80% of the population living in areas meeting performance indicators, increasing to nine countries (47%) in 2012. Performance indicators for timely reporting of PV isolation and characterization were met in four of six World Health Organization (WHO) regions in 2011 and five regions in 2012. To achieve global polio eradication, efforts are needed to improve and maintain AFP surveillance and laboratory performance.
AFP Surveillance
AFP surveillance detects recent paralytic illness of any cause, including poliomyelitis caused by WPV or VDPV. The indicator used to determine if surveillance is sufficiently sensitive to detect PV circulation is the annual proportion of AFP cases that are negative for WPV and VDPV (nonpolio AFP [NPAFP]) among children aged <15 years. Countries in WHO regions certified as polio-free* should achieve an annual NPAFP rate of ≥1 case per 100,000 population aged <15 years; all other countries † should achieve annual rates of ≥2. To ensure sufficiently complete and reliable laboratory analysis, ≥80% of AFP cases should have two stool specimens collected ≥24 hours apart, within 14 days of paralysis onset, arriving in good condition at an accredited GPLN laboratory (adequate specimen). Because national data can mask heterogeneous subnational performance, the AFP surveillance indicators described in this report can be applied to subnational areas and assessed both individually and in combination. To assess population coverage in surveillance, the proportion of the national population residing in the subnational areas where both indicator targets are met is considered. Both national and subnational surveillance performance indicators are used to track GPEI progress.
In 
Environmental Surveillance
The sampling and testing of sewage can identify PV circulation in populations serviced by the sewage system and is used to complement AFP surveillance (8) . Environmental surveillance has been established in two currently polio-endemic countries: Nigeria since 2011 (currently 11 sites in three states) and Pakistan since 2009 (currently 23 sites in four states), and in 22 countries without active WPV transmission: India (currently 15 sites in four states), Egypt (currently 34 sites in 11 cities), and multiple sites in 20 countries of the WHO European Region. In Nigeria, WPV type 1 (WPV1) and VDPV type 2 (VDPV2) were isolated from sewage samples taken from four sites in Sokoto during March-December 2012, including periods when no PV was isolated from persons with AFP. In Kano, sewage sampling began in 2011 at three sites; VDPV2, WPV1, and WPV type 3 isolates were detected during January-September 2012.
In Pakistan, the number of environmental surveillance sampling sites increased from 17 in 2011 to 23 in 2012. WPVs have been isolated from sewage samples since testing began in 2009 from all major cities, even in the absence of confirmed WPV cases detected through AFP surveillance. Samples from Sindh consistently have yielded WPV isolates in the absence of associated WPV-positive AFP cases in the vicinity. In contrast, WPV cases were not detected in Quetta during the second half of 2012; environmental samples from the two Quetta sites also were negative during that period.
In Egypt, WPV1 was isolated from two samples collected in Cairo in December 2012; WPV1 was not detected from samples collected subsequently. The WPV1 sequences from these isolates were similar to WPV1 circulating in northern Sindh, Pakistan. WPV has not been detected in persons with AFP in Egypt since 2004.
Global Polio Laboratory Network
GPLN consists of 146 WHO-accredited PV laboratories in all six WHO regions (5) . GPLN member laboratories follow standardized protocols to 1) identify and isolate PV to confirm NPAFP rate § ≥2 and specimen adequacy ≥80% NPAFP rate ≥2 and specimen adequacy <80% NPAFP rate <2 and specimen adequacy ≥80% NPAFP rate <2 and specimen adequacy <80% Provinces/states with population <100,000 and NPAFP rate <2 Provinces/states with no data or countries not considered Not applicable Abbreviation: NPAFP = nonpolio AFP. * The Global Polio Eradication Initiative 2010-2012 strategic plan sets the following targets for countries with current or recent wild poliovirus transmission and their states/provinces: 1) NPAFP detection rate of two or more cases per 100,000 persons aged <15 years, and 2) adequate stool specimen collection from ≥80% of AFP cases, with specimen adequacy defined as two specimens collected ≥24 hours apart, both within 14 days of paralysis onset, shipped on ice or frozen packs, and arriving in good condition (without leakage or desiccation) at a World Health Organization-accredited laboratory. † Data are for AFP cases with onset during 2012, reported as of February 13, 2012. § Per 100,000 persons aged >15 years. (1-3) , and WPV, Sabin-like PV, § and VDPV (intratypic differentiation [ITD]); and 3) conduct genomic sequencing to monitor pathways of PV transmission by comparing the nucleotide sequence of the VP1 region of the genome from PV isolates (9,10). The two standard laboratory timeliness indicators for stool specimen processing are to report ≥80% ITD results within 7 days of receipt of specimen and ≥80% of sequencing results within 7 days of receipt of specimen. The independent programmatic indicator standard is to report ITD results for ≥80% of isolates within 60 days of paralysis onset of persons with AFP cases; this indicator takes into account the entire interval from onset of paralysis through case notification, investigation, and specimen collection, transport, and testing (the WHO Eastern Mediterranean Region uses a 45-day timeframe). In addition to timeliness, the accuracy and quality of laboratory testing are monitored through an annual accreditation program of onsite reviews and proficiency testing (9) . During 2011-2012, GPLN laboratories in five WHO regions met timeliness indicators for PV isolation. Reporting indicators for onset to ITD results were met in four WHO regions in 2011 and in all WHO regions in 2012 (Table 2) . GPLN tested 215,629 stool specimens in 2012, compared with 206,981 specimens in 2011 (4% increase). In 2012, a total of 395 WPV isolates were detected from all sources (AFP and environmental sample specimens), compared with 1,570 WPV isolates in 2011 (a 75% decrease). In addition, 7,349 Sabin-related PV and 125 VDPV isolates were detected in 2012, compared with 8,569 Sabin-related PV and 93 VDPV isolates detected in 2011. § Demonstrating <6 nucleotide changes from Sabin OPV strains for PV type 2, and <10 changes from Sabin OPV strains for PV types 1 and 3.
During 2012, genomic sequencing identified two WPV1 genotypes and one WPV3 genotype in the African Region: West Africa-B1 (WEAF-B1) type 1 genotype was detected in Nigeria, Niger, and Chad; WEAF-B2 type 1 genotype and WEAF-B type 3 genotype only were detected in Nigeria. In the WHO Eastern Mediterranean Region, South Asia (SOAS) type 1 and SOAS type 3 genotypes were detected in 2012. When genomic sequencing detects >1.5% nucleotide sequence divergence from previously identified PV isolates, this highlights quality gaps in AFP surveillance. Sequence analysis indicated that chains of WPV transmission had been missed by AFP surveillance during 2012 in Afghanistan, Chad, Nigeria, Pakistan, and Niger; chains of VDPV transmission also were missed in Nigeria and Somalia. 
Editorial Note
Notable gains in interrupting WPV transmission have occurred since GPEI was declared a programmatic emergency in January 2012; the number of countries with WPV transmission decreased from 16 in 2011 to five in 2012, and reported WPV cases decreased from 650 to 223, with WPV transmission now primarily in localized "sanctuaries." ¶ AFP surveillance performance indicators met certification-level quality in the majority of countries with PV circulation during 2011-2012 including polio-endemic countries, and improved during this period in Angola, CAR, and DRC; however, critical surveillance gaps remain in parts of Cameroon, Chad, and Niger that border areas of Nigeria with ongoing WPV transmission, and at subnational levels in multiple countries. Environmental sampling continues to complement AFP surveillance in determining areas where PV circulates. GPEI plans to expand environmental surveillance in areas at highest risk for WPV transmission or cVDPV emergence, with consideration of site feasibility and laboratory capacity (2) . Strengthening AFP surveillance becomes increasingly important to detect low-level WPV circulation in its last remaining foci of transmission to target intensified activities, promptly detect any new outbreaks, and eventually achieve, document, certify, and maintain regional polio-free status.
Regional certification of polio-free status only occurs when all member states demonstrate the absence of WPV transmission for 3 consecutive years with surveillance meeting performance targets. Global certification occurs only when all regions are certified poliofree, maintain certification-standard surveillance, and implement posteradication containment measures (2) . The detection of PV in some countries (e.g., Afghanistan, Nigeria, Pakistan, and Somalia) that is highly diverged from previously identified PV isolates indicates that WPV or VDPV transmission remained undetected by AFP surveillance even when AFP performance indicators were met at the state/provincial level (6) . For these reasons, increased emphasis will be placed on activities to ensure that AFP surveillance performance is maintained and improved at all administrative levels throughout each country in 2013. This can be accomplished by 1) tracking implementation of recommendations after surveillance reviews, 2) continuous monitoring of indicators at all administrative levels, 3) retraining staff, 4) improving timely collection and appropriate transportation of stool specimens, and 5) enhancing supervision. Ongoing supervision of active surveillance at health facilities also is needed to ensure optimal surveillance performance, with special attention to populations with a high risk for undetected PV transmission (e.g., mobile and displaced populations). In countries with large populations (e.g., Nigeria and Pakistan), surveillance performance needs to be closely monitored at lower administrative levels (e.g., districts).
The GPEI Polio Eradication and Endgame Strategic Plan for 2013-2018** includes specific efforts to 1) interrupt all PV transmission, 2) certify polio eradication, 3) withdraw OPV, and 4) strengthen routine immunization and surveillance systems as part of the legacy of GPEI. The strategic plan will be submitted to the World Health Assembly in May 2013 to reinvigorate the commitment of countries and other GPEI partners toward polio eradication.
